SYFOVRE™ (Pegcetacoplan) Consent

May 9, 2023

Dear OMIC Insureds:

We are pleased to announce the release of a consent form for FDA-approved SYFOVRE (Pegcetacoplan)

treatment for Geographic Atrophy, a form of Dry Age-Related Macular Degeneration.

If you have questions, contact us for confidential risk management advice at riskmanagement@omic.com

or call us at 1-800-562-6642 and enter 4 for Risk Management.

Sincerely,

Michelle Pineda, MBA
OMIC Risk Manager

CONFIDENTIALITY NOTICE: This correspondence is intended only for the person or entity to which it is addressed and may contain information that is privileged, confidential or otherwise protected from disclosure. Dissemination, distribution or copying of this e-mail or the information herein by anyone other than the intended recipient, or an employee or agent responsible for delivering the message to the intended recipient, is prohibited. If you have received this e-mail in error, please notify us at riskmanagement@omic.com and destroy the original message and all copies.
_________________________________________________

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Six reasons OMIC is the best choice for ophthalmologists in America.

Best at defending claims.

An ophthalmologist pays nearly half a million dollars in premiums over the course of a career. Premium paid is directly related to a carrier’s claims experience. OMIC has a higher win rate taking tough cases to trial, full consent to settle (no hammer) clause, and access to the best experts. OMIC pays 25% less per claim than other carriers. As a result, OMIC has consistently maintained lower base rates than multispecialty carriers in the U.S.

Risk Management

SYFOVRE™ (Pegcetacoplan) Consent